Axsome Therapeutics (AXSM) Misses Q2 EPS by 30c

Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($1.54), $0.30 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $46.01 million versus the consensus estimate of $40.89 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Benchmark Reiterates Buy Rating on Kura Sushi USA Inc. (KRUS) Ahead of Q3 Print
• Axsome starts Phase 3 trial of solriamfetol for adolescent ADHD